Cosmo Pharmaceuticals NV
SIX:COPN

Watchlist Manager
Cosmo Pharmaceuticals NV Logo
Cosmo Pharmaceuticals NV
SIX:COPN
Watchlist
Price: 48.3 CHF -0.1% Market Closed
Market Cap: 847.2m CHF
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one COPN stock under the Base Case scenario is 83.1 CHF. Compared to the current market price of 48.3 CHF, Cosmo Pharmaceuticals NV is Undervalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COPN Relative Value
Base Case
83.1 CHF
Undervaluation 42%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.1
P/S
P/S
Price to Sales
3.1
vs History
98
vs Industry
26
Median 3Y
9.1
Median 5Y
12.5
Industry
2.3
Forward
3.3
More Details
6.3
P/E
P/E
Price to Earnings
6.3
vs History
53
vs Industry
34
Median 3Y
24.3
Median 5Y
8.4
Industry
19.8
Forward
7.9
More Details
5.1
P/OCF
P/OCF
Price to OCF
5.1
vs History
82
vs Industry
42
Median 3Y
28
Median 5Y
30.3
Industry
14.8
More Details
5.4
P/FCFE
P/FCFE
Price to FCFE
5.4
vs History
34
vs Industry
7
Median 3Y
7.2
Median 5Y
-14.7
Industry
22.2
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
93
vs Industry
40
Median 3Y
2.1
Median 5Y
2.3
Industry
1.9
More Details
2.6
EV/S
EV/S
Enterprise Value to Sales
2.6
vs History
98
vs Industry
28
Median 3Y
6.8
Median 5Y
11.9
Industry
2.4
Forward
2.7
More Details
3.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.1
vs History
98
vs Industry
36
Median 3Y
11.2
Median 5Y
20.8
Industry
4.7
More Details
4.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
4.3
vs History
92
vs Industry
38
Median 3Y
16.5
Median 5Y
30.3
Industry
12
Forward
6.4
More Details
4.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
4.7
vs History
82
vs Industry
39
Median 3Y
18.7
Median 5Y
27.4
Industry
14.9
Forward
5.2
More Details
4.3
EV/OCF
EV/OCF
Enterprise Value to OCF
4.3
vs History
82
vs Industry
45
Median 3Y
20.8
Median 5Y
23.1
Industry
13.3
More Details
4.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
4.4
vs History
82
vs Industry
34
Median 3Y
26.7
Median 5Y
29.6
Industry
17.2
More Details
1.4
EV/IC
EV/IC
Enterprise Value to IC
1.4
vs History
79
vs Industry
41
Median 3Y
1.6
Median 5Y
2.1
Industry
1.7
More Details

Multiples Across Competitors

COPN Competitors Multiples
Cosmo Pharmaceuticals NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Cosmo Pharmaceuticals NV
SIX:COPN
773.5m CHF 3.1 6.3 4.3 4.7
US
Eli Lilly and Co
NYSE:LLY
694.1B USD 15.4 65.5 38.2 42.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
370.4B USD 4.2 26.3 12.3 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.2 13.9
CH
Roche Holding AG
SIX:ROG
202.8B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.1B CHF 4.3 18.7 11.3 14.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 3.9 29.9 126 192.4
US
Merck & Co Inc
NYSE:MRK
193.6B USD 3 11.3 7.7 9.1
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
112.8B EUR 2.5 19.6 8.6 12.6
P/E Multiple
Earnings Growth PEG
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average P/E: 23.8
6.3
-27%
N/A
US
Eli Lilly and Co
NYSE:LLY
65.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
19%
1
CH
Roche Holding AG
SIX:ROG
17.6
16%
1.1
CH
Novartis AG
SIX:NOVN
18.7
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
29.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
19.6
28%
0.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average EV/EBITDA: 394.2
4.3
-14%
N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.9
7%
1.4
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126
9%
14
US
Merck & Co Inc
NYSE:MRK
7.7
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.6
6%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Cosmo Pharmaceuticals NV
SIX:COPN
Average EV/EBIT: 1 697.3
4.7
-28%
N/A
US
Eli Lilly and Co
NYSE:LLY
42.2
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.8
9%
1.3
CH
Novartis AG
SIX:NOVN
14.5
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.4
21%
9.2
US
Merck & Co Inc
NYSE:MRK
9.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.6
14%
0.9

See Also

Summary
COPN intrinsic value, competitors valuation, and company profile.
DCF Valuation
COPN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
COPN stock valuation using valuation multiples.
Wall Street Estimates
COPN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
COPN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 247,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.